-
1
-
-
0033920318
-
A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn community programs for clinical research on aids
-
Baxter J.D., Mayers D.L., Wentworth D.N., Neaton J.D., Hoover M.L., Winters M.A., Mannheimer S.B., Thompson M.A., Abrams D.I., Brizz B.J., Ioannidis J.P., and Merigan T.C. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn community programs for clinical research on aids. AIDS 14 (2000) F83-93
-
(2000)
AIDS
, vol.14
-
-
Baxter, J.D.1
Mayers, D.L.2
Wentworth, D.N.3
Neaton, J.D.4
Hoover, M.L.5
Winters, M.A.6
Mannheimer, S.B.7
Thompson, M.A.8
Abrams, D.I.9
Brizz, B.J.10
Ioannidis, J.P.11
Merigan, T.C.12
-
3
-
-
0027920523
-
Update: Mortality Attributable to HIV Infection Among Persons Aged 25-44 Years - United States, 1991 and 1992
-
accessed July 21, 2009
-
Center for Disease Control (CDC), 1993. Update: Mortality Attributable to HIV Infection Among Persons Aged 25-44 Years - United States, 1991 and 1992. MMWR 42, 869-872. http://www.cdc.gov/mmwr/preview/mmwrhtml/00022174.htm (accessed July 21, 2009).
-
(1993)
MMWR
, vol.42
, pp. 869-872
-
-
-
4
-
-
57549085564
-
HIV clinical trial design for antiretroviral development: moving forward
-
Chan-Tack K.M., Struble K.A., Morgensztejn N., Murray J.S., Gulick R., Cheng B., Weller I., and Miller V. HIV clinical trial design for antiretroviral development: moving forward. AIDS 22 (2008) 2419-2427
-
(2008)
AIDS
, vol.22
, pp. 2419-2427
-
-
Chan-Tack, K.M.1
Struble, K.A.2
Morgensztejn, N.3
Murray, J.S.4
Gulick, R.5
Cheng, B.6
Weller, I.7
Miller, V.8
-
5
-
-
0037040360
-
A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy
-
Cohen C.J., Hunt S., Sension M., Farthing C., Conant M., Jacobson S., Nadler J., Verbiest W., Hertogs K., Ames M., Rinehart A.R., and Graham N.M. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16 (2002) 579-588
-
(2002)
AIDS
, vol.16
, pp. 579-588
-
-
Cohen, C.J.1
Hunt, S.2
Sension, M.3
Farthing, C.4
Conant, M.5
Jacobson, S.6
Nadler, J.7
Verbiest, W.8
Hertogs, K.9
Ames, M.10
Rinehart, A.R.11
Graham, N.M.12
-
6
-
-
47949114939
-
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
-
Cooper D., Steigbigel R., Gatell J., Rockstroh J., Katlama C., and Yeni P. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Eng. J. Med. 359 (2008) 355-365
-
(2008)
N. Eng. J. Med.
, vol.359
, pp. 355-365
-
-
Cooper, D.1
Steigbigel, R.2
Gatell, J.3
Rockstroh, J.4
Katlama, C.5
Yeni, P.6
-
7
-
-
0030567824
-
Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
-
the Delta Coordinating Committee
-
Darbyshire, J.H., the Delta Coordinating Committee, 1996. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 348, 283-291.
-
(1996)
Lancet
, vol.348
, pp. 283-291
-
-
Darbyshire, J.H.1
-
8
-
-
0033606540
-
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial
-
Durant J., Clevenbergh P., Halfon P., Delgiudice P., Porsin S., Simonet P., Montagne N., Boucher C.A., Schapiro J.M., and Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353 (1999) 2195-2199
-
(1999)
Lancet
, vol.353
, pp. 2195-2199
-
-
Durant, J.1
Clevenbergh, P.2
Halfon, P.3
Delgiudice, P.4
Porsin, S.5
Simonet, P.6
Montagne, N.7
Boucher, C.A.8
Schapiro, J.M.9
Dellamonica, P.10
-
9
-
-
73549105895
-
-
Etravirine. Raritan, NJ. Tibotec. 2008 (prescribing information). Tibotec Inc. INTELENCE (etravirine) tablet for oral use, prescribing information, revised 02/2008. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6580 (accessed June 11, 2009).
-
Etravirine. Raritan, NJ. Tibotec. 2008 (prescribing information). Tibotec Inc. INTELENCE (etravirine) tablet for oral use, prescribing information, revised 02/2008. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6580 (accessed June 11, 2009).
-
-
-
-
10
-
-
10144244674
-
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimetre. AIDS Clinical Trials Group Study 175 Study Team
-
Hammer S.M., Katzenstein D.A., Hughes M.D., Gundacker H., Schooley R.T., Haubrich R.H., Henry W.K., Lederman M.M., Phair J.P., Niu M., Hirsch M.S., and Merigan T.C. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimetre. AIDS Clinical Trials Group Study 175 Study Team. N. Engl. J. Med. 335 (1996) 1081-1090
-
(1996)
N. Engl. J. Med.
, vol.335
, pp. 1081-1090
-
-
Hammer, S.M.1
Katzenstein, D.A.2
Hughes, M.D.3
Gundacker, H.4
Schooley, R.T.5
Haubrich, R.H.6
Henry, W.K.7
Lederman, M.M.8
Phair, J.P.9
Niu, M.10
Hirsch, M.S.11
Merigan, T.C.12
-
11
-
-
0442268112
-
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
-
AIDS Clinical Trials Group 320 Study Team
-
AIDS Clinical Trials Group 320 Study Team, Hammer S.M., Squires K.E., Hughes M.D., Grimes J.M., Demeter L.M., Currier J.S., Eron Jr. J.J., Feinberg J.E., Balfour Jr. H.H., Deyton L.R., Chodakewitz J.A., and Fischl M.A. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337 (1997) 725-733
-
(1997)
N. Engl. J. Med.
, vol.337
, pp. 725-733
-
-
Hammer, S.M.1
Squires, K.E.2
Hughes, M.D.3
Grimes, J.M.4
Demeter, L.M.5
Currier, J.S.6
Eron Jr., J.J.7
Feinberg, J.E.8
Balfour Jr., H.H.9
Deyton, L.R.10
Chodakewitz, J.A.11
Fischl, M.A.12
-
12
-
-
0031740223
-
Meta-analysis of antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death
-
Hill A.M., DeMasi R., and Dawson D. Meta-analysis of antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death. Antivir Ther. 3 (1998) 139-145
-
(1998)
Antivir Ther.
, vol.3
, pp. 139-145
-
-
Hill, A.M.1
DeMasi, R.2
Dawson, D.3
-
13
-
-
17344390474
-
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management
-
Hirsch M.S., Conway B., D'Aquila R.T., Johnson V.A., Brun-Vezinet F., Clotet B., Demeter L.M., Hammer S.M., Jacobsen D.M., Kuritzkes D.R., Loveday C., Mellors J.W., Vella S., and Richman D.D. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 279 (1998) 1984-1991
-
(1998)
JAMA
, vol.279
, pp. 1984-1991
-
-
Hirsch, M.S.1
Conway, B.2
D'Aquila, R.T.3
Johnson, V.A.4
Brun-Vezinet, F.5
Clotet, B.6
Demeter, L.M.7
Hammer, S.M.8
Jacobsen, D.M.9
Kuritzkes, D.R.10
Loveday, C.11
Mellors, J.W.12
Vella, S.13
Richman, D.D.14
-
14
-
-
73549104777
-
-
Holmes, C., Coggin, W., Jamieson, D., Mihm, H., Savio, P., Hope, M., Ryan, C., Moloney-Kitts, M., Dybul, M., 2009. Measuring progress in reducing the costs of ARV drugs purchased by the President's Emergency Plan for AIDS Relief, 2005 to 2007. CROI 2009, 612. www.retroconference.org/2009/Abstracts/35741.htm (accessed July 16, 2009).
-
Holmes, C., Coggin, W., Jamieson, D., Mihm, H., Savio, P., Hope, M., Ryan, C., Moloney-Kitts, M., Dybul, M., 2009. Measuring progress in reducing the costs of ARV drugs purchased by the President's Emergency Plan for AIDS Relief, 2005 to 2007. CROI 2009, 612. www.retroconference.org/2009/Abstracts/35741.htm (accessed July 16, 2009).
-
-
-
-
15
-
-
0024508058
-
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
-
Larder B.A., Darby G., and Richman D.D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243 (1989) 1731-1734
-
(1989)
Science
, vol.243
, pp. 1731-1734
-
-
Larder, B.A.1
Darby, G.2
Richman, D.D.3
-
16
-
-
34347354196
-
Efficacy and safty of tMS125 (etraviringe) in treatment-experienced HIV-1 infected patients in DUET-2: 24-week results from a randomized, double-blind, placebo-controlled trial
-
Lazzarin A., Campbell T., Clotet B., Johnson M., Katlama C., and Moll A. Efficacy and safty of tMS125 (etraviringe) in treatment-experienced HIV-1 infected patients in DUET-2: 24-week results from a randomized, double-blind, placebo-controlled trial. Lancet 370 (2007) 39-48
-
(2007)
Lancet
, vol.370
, pp. 39-48
-
-
Lazzarin, A.1
Campbell, T.2
Clotet, B.3
Johnson, M.4
Katlama, C.5
Moll, A.6
-
17
-
-
34347327010
-
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-1: 24-week results from a randomized, double-blind, placebo-controlled trial
-
Madruga J.V., Cahn P., Grinsztejn B., Haubrich R., Lalezari J., and Mills A. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-1: 24-week results from a randomized, double-blind, placebo-controlled trial. Lancet 370 (2007) 29-38
-
(2007)
Lancet
, vol.370
, pp. 29-38
-
-
Madruga, J.V.1
Cahn, P.2
Grinsztejn, B.3
Haubrich, R.4
Lalezari, J.5
Mills, A.6
-
18
-
-
73549097488
-
-
Maraviroc. New London, CT, Pfizer, 2007 (prescribing information). Pfizer Inc., SELZENTRY (maraviroc) tablet, film coated for oral use, prescribing information, revised 12/2008. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8731 (accessed June 15, 2009).
-
Maraviroc. New London, CT, Pfizer, 2007 (prescribing information). Pfizer Inc., SELZENTRY (maraviroc) tablet, film coated for oral use, prescribing information, revised 12/2008. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8731 (accessed June 15, 2009).
-
-
-
-
19
-
-
0041336973
-
Congress, the FDA, and the fair development of new medications for children
-
Available at: http://pediatrics.aappublications.org/cgi/content/full/112/3/669
-
McKinney Jr. R.E. Congress, the FDA, and the fair development of new medications for children. Pediatrics 112 (2003) 669-670. http://pediatrics.aappublications.org/cgi/content/full/112/3/669 Available at: http://pediatrics.aappublications.org/cgi/content/full/112/3/669
-
(2003)
Pediatrics
, vol.112
, pp. 669-670
-
-
McKinney Jr., R.E.1
-
20
-
-
0037192551
-
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial
-
Meynard J.L., Vray M., Morand-Joubert L., Race E., Descamps D., Peytavin G., Matheron S., Lamotte C., Guiramand S., Costagliola D., Brun-Vézinet F., Clavel F., and Girard P.M. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 16 (2002) 727-736
-
(2002)
AIDS
, vol.16
, pp. 727-736
-
-
Meynard, J.L.1
Vray, M.2
Morand-Joubert, L.3
Race, E.4
Descamps, D.5
Peytavin, G.6
Matheron, S.7
Lamotte, C.8
Guiramand, S.9
Costagliola, D.10
Brun-Vézinet, F.11
Clavel, F.12
Girard, P.M.13
-
21
-
-
0032903843
-
The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs
-
Murray J.S., Elashoff M., Iacono-Connors L.C., Cvetkovich T.A., and Struble K.A. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS 13 (1999) 797-804
-
(1999)
AIDS
, vol.13
, pp. 797-804
-
-
Murray, J.S.1
Elashoff, M.2
Iacono-Connors, L.C.3
Cvetkovich, T.A.4
Struble, K.A.5
-
22
-
-
2642709177
-
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
-
Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., and Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338 (1998) 853-860
-
(1998)
N. Engl. J. Med.
, vol.338
, pp. 853-860
-
-
Palella Jr., F.J.1
Delaney, K.M.2
Moorman, A.C.3
Loveless, M.O.4
Fuhrer, J.5
Satten, G.A.6
Aschman, D.J.7
Holmberg, S.D.8
-
23
-
-
73549084494
-
-
Raltegravir. Whitehouse Station, NJ. Merck, 2007 (prescribing information). Merck & Co., Inc. ISENTRESS (raltegravir) tablet, film coated for oral use, prescribing information, revised 2/2009. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=9335 (accessed June 15, 2009).
-
Raltegravir. Whitehouse Station, NJ. Merck, 2007 (prescribing information). Merck & Co., Inc. ISENTRESS (raltegravir) tablet, film coated for oral use, prescribing information, revised 2/2009. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=9335 (accessed June 15, 2009).
-
-
-
-
24
-
-
10144258702
-
Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimetre. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS
-
Saravolatz L.D., Winslow D.L., Collins G., Hodges J.S., Pettinelli C., Stein D.S., Markowitz N., Reves R., Loveless M.O., Crane L., Thompson M., and Abrams D. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimetre. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. N. Engl. J. Med. 335 (1996) 1099-1106
-
(1996)
N. Engl. J. Med.
, vol.335
, pp. 1099-1106
-
-
Saravolatz, L.D.1
Winslow, D.L.2
Collins, G.3
Hodges, J.S.4
Pettinelli, C.5
Stein, D.S.6
Markowitz, N.7
Reves, R.8
Loveless, M.O.9
Crane, L.10
Thompson, M.11
Abrams, D.12
-
25
-
-
73549118762
-
-
Senate Report 107-79, 2001. Best Pharmaceuticals for Children Act. Available at: http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=107_cong_reports&docid=f:sr079.107.pdf (accessed May 18, 2009).
-
Senate Report 107-79, 2001. Best Pharmaceuticals for Children Act. Available at: http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=107_cong_reports&docid=f:sr079.107.pdf (accessed May 18, 2009).
-
-
-
-
26
-
-
47949120697
-
Raltegravir with optimized background therapy for resistant HIV-1 infection
-
Steinbigel R., Cooper D., Kumar P., Eron J., Schechter M., and Markowitz M. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359 (2008) 339-354
-
(2008)
N. Engl. J. Med.
, vol.359
, pp. 339-354
-
-
Steinbigel, R.1
Cooper, D.2
Kumar, P.3
Eron, J.4
Schechter, M.5
Markowitz, M.6
-
27
-
-
20644469472
-
Antiretroviral therapies for treatment-experienced patients: current status and research challenges
-
Struble K., Murray J., Cheng B., Gegeny T., Miller V., and Gulick R. Antiretroviral therapies for treatment-experienced patients: current status and research challenges. AIDS 19 (2005) 747-756
-
(2005)
AIDS
, vol.19
, pp. 747-756
-
-
Struble, K.1
Murray, J.2
Cheng, B.3
Gegeny, T.4
Miller, V.5
Gulick, R.6
-
28
-
-
0037169170
-
Clinical utility of HIV-1 genotyping and expert advice: the Havana trial
-
Tural C., Ruiz L., Holtzer C., Schapiro J., Viciana P., González J., Domingo P., Boucher C., Rey-Joly C., and Clotet B. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16 (2002) 209-218
-
(2002)
AIDS
, vol.16
, pp. 209-218
-
-
Tural, C.1
Ruiz, L.2
Holtzer, C.3
Schapiro, J.4
Viciana, P.5
González, J.6
Domingo, P.7
Boucher, C.8
Rey-Joly, C.9
Clotet, B.10
-
29
-
-
0000211665
-
21 CFR Part 201: Specific requirements on content and format of labeling for human prescription drugs; Revision of 'Pediatric Use' subsection in the labeling, final rule
-
Available at:, accessed on May 15, 2009
-
U.S. Food and Drug Administration (FDA), 1994. 21 CFR Part 201: specific requirements on content and format of labeling for human prescription drugs; Revision of 'Pediatric Use' subsection in the labeling, final rule. Federal Register, 59, 64240-64250. Available at: http://frwebgate4.access.gpo.gov/cgi-bin/TEXTgate.cgi?WAISdocID=868741362968+1+1+0&WAISaction=retrieve (accessed on May 15, 2009).
-
(1994)
Federal Register
, vol.59
, pp. 64240-64250
-
-
-
30
-
-
73549087390
-
-
U.S. Food and Drug Administration, Antiviral Drugs Advisory Committee transcripts, July 14-16, Available at:, accessed July 13, 2009
-
U.S. Food and Drug Administration, Antiviral Drugs Advisory Committee transcripts, July 14-16, 1997. Available at: http://www.fda.gov/ohrms/dockets/ac/cder97t.htm#Antiviral%20Drugs%20Advisory%20Committee (accessed July 13, 2009).
-
(1997)
-
-
-
31
-
-
73549087829
-
-
U.S. Food and Drug Administration Modernization Act FDAMA, Available at:, accessed July 13, 2009
-
U.S. Food and Drug Administration Modernization Act (FDAMA), 1997. Available at: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDAMA/FullTextofFDAMAlaw/default.htm (accessed July 13, 2009).
-
(1997)
-
-
-
32
-
-
73549095740
-
-
U.S. Food and Drug Administration (FDA), 1998. Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and Biological Products in Pediatric Patients; Final Rule, 63 Fed. Reg. 66,632. Available at: www.fda.gov (accessed on May 27, 2009).
-
U.S. Food and Drug Administration (FDA), 1998. Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and Biological Products in Pediatric Patients; Final Rule, 63 Fed. Reg. 66,632. Available at: www.fda.gov (accessed on May 27, 2009).
-
-
-
-
33
-
-
73549125441
-
-
of the Federal Food, Drug, and Cosmetic Act. Available at:, accessed May 29, 2009
-
U.S. Food and Drug Administration (FDA), 1999. Guidance for Industry: Qualifying for Pediatric Exclusivity Under Section 505A of the Federal Food, Drug, and Cosmetic Act. Available at: www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM049924.pdf (accessed May 29, 2009).
-
(1999)
Guidance for Industry: Qualifying for Pediatric Exclusivity Under Section
, vol.505 A
-
-
-
34
-
-
73549113518
-
-
U.S. Food and Drug Administration Antiviral Drugs Advisory Committee transcript, January 11, Available at:, accessed July 13, 2009
-
U.S. Food and Drug Administration Antiviral Drugs Advisory Committee transcript, January 11, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/cder01.htm#Anti-Viral (accessed July 13, 2009).
-
(2001)
-
-
-
37
-
-
73549084708
-
-
U.S. Food and Drug Administration Amendments Act of 2007. Title IV: Pediatric Research Equity Act of 2007, January 4, 2007 (Public Law 110-85). Available at: www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM049870.pdf (accessed May 4, 2009)
-
U.S. Food and Drug Administration Amendments Act of 2007. Title IV: Pediatric Research Equity Act of 2007, January 4, 2007 (Public Law 110-85). Available at: www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM049870.pdf (accessed May 4, 2009)
-
-
-
-
38
-
-
73549092907
-
-
U.S. Food and Drug Administration, Code of Federal Regulations, Title 21, Part 312, Subpart E, revised April 1, 2009. Drugs Intended to Treat Life-threatening and Severely-debilitating Illnesses. Available at: +2+1+0&WAISaction=retrieve accessed July 13, 2009
-
U.S. Food and Drug Administration, Code of Federal Regulations, Title 21, Part 312, Subpart E, revised April 1, 2009. Drugs Intended to Treat Life-threatening and Severely-debilitating Illnesses. Available at: http://frwebgate1.access.gpo.gov/cgi-bin/TEXTgate.cgi?WAISdocID=51022462543+2+1+0&WAISaction=retrieve (accessed July 13, 2009).
-
-
-
-
39
-
-
73549102156
-
-
U.S. Food and Drug Administration, Code of Federal Regulations, Title 21, Part 314, Subpart H, revised April 1, 2009. Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses. Available at: +1+1+0&WAISaction=retrieve accessed July 13, 2009
-
U.S. Food and Drug Administration, Code of Federal Regulations, Title 21, Part 314, Subpart H, revised April 1, 2009. Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses. Available at: http://frwebgate1.access.gpo.gov/cgi-bin/TEXTgate.cgi?WAISdocID=51039466299+1+1+0&WAISaction=retrieve (accessed July 13, 2009).
-
-
-
-
40
-
-
73549116992
-
-
U.S. President's Emergency Plan for AIDS Relief (PEPFAR), 2009. PEPFAR Overview. http://www.pepfar.gov/press/81352.htm (accessed July 16, 2009).
-
U.S. President's Emergency Plan for AIDS Relief (PEPFAR), 2009. PEPFAR Overview. http://www.pepfar.gov/press/81352.htm (accessed July 16, 2009).
-
-
-
-
41
-
-
73549083610
-
-
U.S. President's Emergency Plan for AIDS Relief (PEPFAR), 2009. About PEPFAR, Treatment. http://www.pepfar.gov/about/c19384.htm (accessed July 16, 2009).
-
U.S. President's Emergency Plan for AIDS Relief (PEPFAR), 2009. About PEPFAR, Treatment. http://www.pepfar.gov/about/c19384.htm (accessed July 16, 2009).
-
-
-
-
42
-
-
73549103796
-
-
U.S. President's Emergency Plan for AIDS Relief (PEPFAR), 2009. Celebrating Life: Latest PEPFAR Results. http://www.pepfar.gov/documents/organization/115411.pdf (accessed July 16, 2009).
-
U.S. President's Emergency Plan for AIDS Relief (PEPFAR), 2009. Celebrating Life: Latest PEPFAR Results. http://www.pepfar.gov/documents/organization/115411.pdf (accessed July 16, 2009).
-
-
-
-
43
-
-
0003732386
-
-
accessed July 21, 2009
-
World Health Organization (WHO), 2003. The World Health Report, http://www.who.int/whr/2003/chapter1/en/index3.html (accessed July 21, 2009).
-
(2003)
The World Health Report
-
-
|